Thioquinapiperifil dihydrochloride is primarily explored for its potential therapeutic applications in the field of neurology and cognitive health. It has been studied for its role as a phosphodiesterase inhibitor, which may enhance cognitive functions such as memory, learning, and attention. This compound is of particular interest in the development of treatments for neurodegenerative disorders, including Alzheimer's disease and other forms of dementia, where cognitive decline is a significant concern. Additionally, its neuroprotective properties are being investigated to understand its potential in mitigating brain damage caused by ischemic events, such as strokes. Research is ongoing to determine its efficacy and safety in clinical settings, with the aim of providing new therapeutic options for patients with cognitive impairments.